Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2008 1
2009 2
2011 4
2012 4
2013 2
2014 5
2015 3
2016 4
2017 4
2018 8
2019 8
2020 6
2021 8
2022 12
2023 10
2024 13
2025 19
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.
Sakai D, Kadowaki S, Kawabata R, Hara H, Satake H, Takahashi M, Takeno A, Imai H, Minashi K, Kawakami T, Boku S, Matsuyama J, Sakamoto Y, Sawada K, Kataoka M, Kawakami H, Shimokawa T, Boku N, Satoh T. Sakai D, et al. Among authors: kawakami t. J Clin Oncol. 2025 Jul;43(19):2196-2207. doi: 10.1200/JCO.24.01119. Epub 2025 May 23. J Clin Oncol. 2025. PMID: 40408613 Free PMC article. Clinical Trial.
Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study).
Shoji H, Kudo-Saito C, Nagashima K, Imazeki H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Muro K, Aoki K, Boku N. Shoji H, et al. Among authors: kawakami t. J Immunother Cancer. 2024 Nov 3;12(11):e010174. doi: 10.1136/jitc-2024-010174. J Immunother Cancer. 2024. PMID: 39489543 Free PMC article.
A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer.
Baba K, Suzuki N, Imamura CK, Booka E, Takeuchi M, Takahari D, Kawakami T, Kawakubo H, Kitagawa C, Kono Y, Ogura K, Kito Y, Saito K, Yamamoto S, Takeuchi H, Kudo T, Tsunoda T, Mizukami T, Yamaguchi T, Shoji H, Saito K, Tanoue K, Baba E, Nagashima K, Boku N. Baba K, et al. Among authors: kawakami t. BMC Cancer. 2025 Apr 12;25(1):675. doi: 10.1186/s12885-025-14084-1. BMC Cancer. 2025. PMID: 40221699 Free PMC article. Clinical Trial.
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS.
Komori A, Hironaka S, Kadowaki S, Mitani S, Furuta M, Kawakami T, Makiyama A, Takegawa N, Sugiyama K, Hirano H, Ando T, Matsushima T, Chida A, Kashiwada T, Komoda M, Matsumoto T, Oda H, Yabusaki H, Kawakami H, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K; West Japan Oncology Group (WJOG). Komori A, et al. Among authors: kawakami t. Gastric Cancer. 2025 Mar;28(2):301-308. doi: 10.1007/s10120-024-01579-2. Epub 2024 Dec 31. Gastric Cancer. 2025. PMID: 39738793
111 results